• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Mayo Clinic, SandboxAQ Expand Collaboration to Advance AI Cardiac Diagnostics in Amyloidosis

by Fred Pennic 01/17/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Image by freepik

What You Should Know:

– Mayo Clinic is expanding its collaboration with SandboxAQ, a provider of artificial intelligence (AI) medical apps to explore the use of electrocardiography (ECG) and magnetocardiography (MCG) technologies for characterizing disease progression and treatment response in patients with amyloidosis.

– The expanded partnership highlights the potential of combining AI and advanced sensing technology to revolutionize cardiac diagnostics.

Improved Detection and Monitoring of Amyloidosis and Other Cardiac Conditions

Amyloidosis is a condition characterized by the buildup of abnormal protein deposits in organs and tissues, including the heart. Early diagnosis and accurate monitoring are crucial for effective management, but current tools often fall short in detecting subtle changes in cardiac function.

The expanded collaboration aims to address this challenge by integrating the established reliability of ECG with the cutting-edge sensitivity of MCG. MCG is a non-invasive technology that measures the magnetic fields generated by the heart’s electrical activity, providing a more detailed picture of cardiac function compared to ECG alone.

By combining these two modalities with SandboxAQ’s advanced AI algorithms, the partnership seeks to develop a novel diagnostic solution that offers deeper insights into the electrical and magnetic activity of the heart. This approach has the potential to:

  • Improve early detection of amyloidosis: Identify subtle changes in cardiac function that may be missed by traditional methods.
  • Enhance disease monitoring: Track disease progression and treatment response more accurately over time.
  • Enable personalized treatment: Guide clinical decision-making and optimize treatment strategies for individual patients.

“By uniting AQMed’s technical innovation with Mayo Clinic’s renowned research and clinical excellence, we aim to make a meaningful impact on the lives of amyloidosis patients across the globe in the near future,” said Kit Yee Au-Yeung, GM of SandboxAQ’s AQMed division.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Cardiac Monitoring, heart disease

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Evernorth Health Services Invests $3.5B in Shields Health Solutions

Evernorth Health Services Invests $3.5B in Shields Health Solutions

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A:Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Femtech: Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

Sage Growth Partners Report: Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |